Effect of inner physical properties on powder adhesion in inhalation capsules in case of a high resistance device

Otake,Hiroko; Minami,Misa; Yamaguchi,Mizuki; Akiyama,Sawako; Inaba,Kazunori; Nagai,Noriaki

doi:10.3892/etm.2021.10788

Effect of inner physical properties on powder adhesion in inhalation capsules in case of a high resistance device

Authors:
- Hiroko Otake
- Misa Minami
- Mizuki Yamaguchi
- Sawako Akiyama
- Kazunori Inaba
- Noriaki Nagai
View Affiliations

Affiliations: Faculty of Pharmacy, Kindai University, Higashi‑Osaka, Osaka 577‑8502, Japan
Published online on: September 23, 2021 https://doi.org/10.3892/etm.2021.10788
Article Number: 1353
Copyright: © Otake et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The inhalation performance of a dry powder inhaler (DPI) depends on the inhalation patterns of patients, inhalation particle characteristics and inhalation devices. In capsule‑based DPIs, the capsule plays an important role in the dispersion of inhalation particles. The present study investigated the effects of inner physical properties of capsules on drug release from capsules‑based DPIs with high resistance device. Atomic force microscopy (AFM) was used to evaluate the capsule physical properties, such as the capsule inner structure and surface potential, of three capsules with different compositions (G‑Cap, PEG/G‑Cap, and HPMC‑Cap). As a model dry powder for capsule‑based DPIs, the dry powder in Spiriva^® Inhalation Capsules containing tiotropium bromide was used. Inhalation performance was evaluated using a twin‑stage liquid impinge and Handihaler^® (flow rate 30 l/min). The results indicated that the capsule inner surface presented with numerous valleys and mountains, regardless of the capsule type. Furthermore, the valley and mountain areas on the capsule inner surface showed a significantly higher or lower surface potential. Following inhalation of capsule‑based DPIs, the drug remained in the valleys on the capsule inner surface; however, no significant difference was observed in the drug release from capsule and lung drug delivery. Therefore, inhalation performance in capsule‑based DPIs when a high resistance device, such as Handihaler^®, is used at an appropriately flow rate is not markedly affected by the physical properties of the capsule inner surface due to capsule composition.

View Figures

View References

1	Claus S, Weiler C, Schiewe J and Friess W: How can we bring high drug doses to the lung? J Pharm Biopharm. 86:1–6. 2014.PubMed/NCBI View Article : Google Scholar
2	Yang MY, Chan JG and Chan HK: Pulmonary drug delivery by powder aerosols. J Control Rel. 193:228–240. 2014.PubMed/NCBI View Article : Google Scholar
3	Tonnis WF, Lexmond AJ, Frijlink HW, de Bore AH and Hinrichs WL: Devices and formulations for pulmonary vaccination. Expert Opin Drug Deliv. 10:1383–1397. 2013.PubMed/NCBI View Article : Google Scholar
4	Bouwmeester C, Kraft J and Bungay KM: Optimizing inhaler use by pharmacist-provided education to community-dwelling elderly. Respir Med. 109:1363–1368. 2015.PubMed/NCBI View Article : Google Scholar
5	Broeders ME, Vincken W, Corbetta L and Group AW: The ADMIT series-Issues in inhalation therapy. 7. Ways to improve pharmacological management of COPD: The importance of inhaler choice and inhalation technique. Prime Care Respir J. 20:338–343. 2011.PubMed/NCBI View Article : Google Scholar
6	Cochrane MG, Bala MV, Downs KE, Mauskopf J and Ben-Joseph RH: Inhaled corticosteroids for asthma therapy: Patient compliance, devices, and inhalation technique. Chest. 117:542–550. 2000.PubMed/NCBI View Article : Google Scholar
7	Baily MM, Gorman EM, Munson EJ and Berkland C: Pure insulin nanoparticle agglomerates for pulmonary delivery. Lungmuir. 24:13614–13620. 2008.PubMed/NCBI View Article : Google Scholar
8	Weer JG and Miller DP: Formulation design of dry powders for inhalation. J Pharm Sci. 104:3259–3288. 2015.PubMed/NCBI View Article : Google Scholar
9	Stocks J and Hislop AA: Structure and function of the respiratory system: Developmental aspects and their relevance to aerosol therapy. In: Drug Delivery to the Lung: Clinical Aspects. Bisgaard H, O'Callaghan C, Smaldone CG (eds.) Marcel Dekker, Inc., New York, NY pp47-104, 2002.
10	Lavorini F, Pistolesi M and Usmani OS: Recent advances in capsule-based dry powder inhaler technology. Multidiscip Respir Med. 12(11)2017.PubMed/NCBI View Article : Google Scholar
11	Berkenfeld K, Lamprecht A and McConville JT: Devices for dry powder drug delivery to the lung. AAPS PharmSciTech. 16:479–490. 2015.PubMed/NCBI View Article : Google Scholar
12	Faulhammer E, Flink M, Liusa M, Lawrence SM, Biserni S, Calzolari V and Khinast JG: Low-dose capsule filling of inhalation products: Critical material attributes and process parameters. Int J Pharm. 473:617–626. 2014.PubMed/NCBI View Article : Google Scholar
13	Wauthoz N, Hennia I, Dejaeger B, Ecenarro S and Amighi K: Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation. Int J Pharm. 530:415–429. 2017.PubMed/NCBI View Article : Google Scholar
14	Smith IJ, Bell J, Bowman N, Everard M, Stein S and Weer JG: Inhaler devices: What remains to be done? J Aerol Med Pulm Drug Deliv. (Suppl 2):S25–S37. 2010.PubMed/NCBI View Article : Google Scholar
15	Steckel H and Muller BW: In-vitro evaluation of dry powder inhalers 1: Drug deposition of commonly used devices. Int J Phar. 154:19–29. 1997.
16	Vidgren M, Kärkkäinen A, Karjalainen P, Paronen P and Nuutinen J: Effect of powder inhaler design on drug deposition in the respiratory tract. Int J Pharm. 42:211–216. 1988.
17	Chew NY, Shekunov BY, Tong HH, Chow AH, Savage C, Wu J and Chan H: Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci. 94:2289–2300. 2005.PubMed/NCBI View Article : Google Scholar
18	Otake H, Okuda T and Okamoto H: Development of spray-freeze dried powders for inhalation with high inhalation performance and antihygroscopic property. Chem Pharm Bull (Tokyo). 64:239–245. 2016.PubMed/NCBI View Article : Google Scholar
19	Li HY, Seville PC, Williamson IJ and Birchall JC: The use of amino acids to enhance the aerosolisation of spray-dried powders for pulmonary gene therapy. J Gene Med. 7:343–353. 2005.PubMed/NCBI View Article : Google Scholar
20	Ungaro F, Giovino C, Coletta C, Sorrentino R, Miro A and Quaglia F: Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pharm Sci. 41:60–70. 2010.PubMed/NCBI View Article : Google Scholar
21	Duan J, Vogt FG, Li X, Hayes Jr D and Mansour HM: Design, characterization, and aerolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine. 8:3489–3505. 2013.PubMed/NCBI View Article : Google Scholar
22	Wauthoz N, Hennia I, Ecenarro S and Amighi K: Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend. Int J Pharm. 553:47–56. 2018.PubMed/NCBI View Article : Google Scholar
23	Saleem IY, Diez F, Jones BE and Polo L: Investigation on the aerosol performance of dry powder inhalation hypromellose capsules with different lubricant levels. Int J Pharm. 492:258–263. 2015.PubMed/NCBI View Article : Google Scholar
24	Horhota ST, van Noord JA, Verkleij CB, Bour LJ, Sharma A, Trunk M and Cornelissen PJ: In vitro, pharmacokinetic, pharmacodynamic, and safety comparisons of single and combined administration of Tiotropium and Salmeterol in COPD patients using different dry powder inhalers. AAPS J. 17:871–880. 2015.PubMed/NCBI View Article : Google Scholar
25	Hira D, Koide H, Nakamura S, Okada T, Ishizeki K, Yamaguchi M, Koshiyama S, Oguma T, Ito K, Funayama S, et al: Assessment of inhalation flow patterns of soft mist inhaler co-prescribed with dry powder inhaler using inspiratory flow meter for multi inhalation devices. PLoS One. 13(e0193082)2018.PubMed/NCBI View Article : Google Scholar
26	García R and Pérez R: Dynamic atomic force microscopy methods. Surf Sci Rep. 47:197–301. 2002.
27	Nagata S: Gellulose capsules-an alternative to gelatin. In: Biolodical Polymers and Polymer Therapeutics. Chiellini E, Sunamoto J, Migliaresi C, Ottenbrite RM, Cohn D (eds). Kluwer Academics/Plenum Publishers, New York, NY, pp 53-62, 2001.
28	Coate MS, Fletcher DF, Chan HK and Raper JA: The role of capsule on the performance of a dry powder inhaler using computational and experimental analysis. Pharm Res. 22:923–932. 2005.PubMed/NCBI View Article : Google Scholar
29	Mehta PP, Kadam SS and Pawar AP: Effect of USP induction ports and modified glass sampling apparatus on aerosolization performance of lactose carrier-based fluticasone propionate dry powder inhaler. J Drug Deliv Sci Technol. 58(101794)2020.
30	Timsina MP, Martin GP, Marriott C, Ganderton D and Yianneskis M: Drug delivery to the respiratory tract using dry powder inhalers. Int J Pharm. 101:1–13. 1994.